StockTipsArenaBeta

BUY Windlas Biotech Limited — Vishnu Kant Upadhyay, Master Capital Services

BUYWindlas Biotech Limited

byVishnu Kant Upadhyay, Master Capital ServicesHorizon: NA (inferred Swing (≤2wk))17 Aug 2026via NDTV Profit

Entry₹953.7Inferred
Target₹1,100
Total upside +15.34% (call closed)
Stop loss₹880-7.73% risk
At expiry₹1,00128 Aug 2026, 3:30 pm
Expired+4.96%
Follow Vishnu Kant Upadhyay for new calls(11% target hit, 63 closed calls)Get alertsWatch WINDLAS for new buy/sell callsGet alertsSee 1 active Swing call on WINDLASSee 97 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 28 Aug 2026
1 supporting1 neutral0 opposing
Supports the BUY call (1)

Windlas Biotech Limited reported Q1 FY27 financial results with revenue of Rs 248 crores, an 18% YoY growth. Adjusted EBITDA grew 26% YoY to Rs 34 crores, and Adjusted PAT grew 37% YoY to Rs 25 crores

NSE · Press Release·10 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (1)

Windlas Biotech Limited has announced its financial results for the first quarter of the fiscal year 2027.

BSE · Company Update·10 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.